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a b s t r a c t
The HIV-1 envelope glycoprotein, gp120, binds the host cell receptor, CD4, in the initial step of HIV viral
entry and infection. This process is an appealing target for the development of inhibitory drugs and
neutralizing antibodies. To study gp120 binding and intracellular trafﬁcking, we engineered a ﬂuorescent
fusion of the humanized gp120 JRFL HIV-1 variant and GFP. Gp120-sfGFP is glycosylated with human
sugars, robustly expressed, and secreted from cultured human cells. Protein dynamics, quality control,
and trafﬁcking can be visualized in live cells. The fusion protein can be readily modiﬁed with different
gp120 variants or ﬂuorescent proteins. Finally, secreted gp120-sfGFP enables a sensitive and easy
binding assay that can quantitatively screen potential inhibitors of gp120-CD4 binding on live cells via
ﬂuorescence imaging or laser scanning cytometry. This adaptable research tool should aid in studies of
gp120 cell biology and the development of novel anti-HIV drugs.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Despite several successes in development of HIV therapeutics,
an effective vaccine and cure remain elusive (Schiffner et al., 2013).
The ﬁrst step in viral infection is the binding of the HIV-1 envelope
glycoprotein 120 (gp120) to the cellular receptor CD4, which is a
major target for drug and vaccine development. Two drugs,
Maraviroc and Enfuvirtide, inhibit the subsequent interactions
between gp41 and co-receptors CCR5 or CXCR4, but there are no
approved drugs to inhibit gp120 binding to CD4. Broadly neutra-
lizing antibodies (BNAbs), named for their ability to neutralize
infectivity of a broad spectrum of primary HIV strains, have been
identiﬁed in HIV-1 infected individuals (Simek et al., 2009) and
these may aid in identiﬁcation of gp120 epitopes that could be
targeted for vaccine and drug development (Mascola and Haynes,
2013). Of particular interest are antibodies targeting the CD4-
binding site of gp120 (Li et al., 2007). This interaction is critical for
viral attachment, independent of HIV-1 virus strain. Furthermore,
BNAbs potentially could be exploited to target steps of the viral life
cycle that are not included in current ART (anti-retroviral therapy)
drug regimens, to prevent viral rebound after cessation of ART, and
to treat individuals who do not tolerate ART or develop drug
resistance (Klein et al., 2013). In a related approach, potent small
molecule inhibitors of viral entry that modulate binding of gp120
and CD4 have been developed. These inhibitors include BMS-
378806, which binds gp120 and disrupts conformational changes
required for binding to CD4 (Si et al., 2004), and the recently
identiﬁed CD4-mimetic compounds, such as NBD-556 (Schon
et al., 2006) and JR-II-191 (Haim et al., 2009), which can bind
monomeric gp120, and block interactions with CD4. Finally it is
important to note that gp120, itself, (even in the absence of virus
and CD4) is pathogenic in HIV-associated neurocognitive disorders
(HAND). Binding of gp120 to receptors unrelated to CD4 on
neurons can trigger apoptosis (Rao et al., 2014) and emphasizes
the importance of studying gp120 interactions with cells.
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An easily modiﬁable ﬂuorescent gp120 protein could aid in the
study of HAND, the development of new therapeutics, and to
evaluate inhibitors of CD4 binding. While commercial ﬂuores-
cently labeled puriﬁed gp120 has been available, they have
suboptimal characteristics. The products have been FITC dye-
labeled gp120 expressed by insect cells, which is suboptimal
because: 1) protein glycosylation patterns differ greatly between
insect and human cells (Kost et al., 2005), which profoundly alters
gp120 afﬁnity for various BNAbs (Kong et al., 2010); 2) FITC is pH
sensitive and highly prone to photobleaching (Swanson, 1989);
3) chemical dye-labeling, including FITC, is random and could
potentially interfere with CD4 or antibody binding domains; and
4) investigators cannot modify the labeled commercial reporter
with mutations or dyes for different assay needs. Here, we
describe a new ﬂuorescent protein (FP) tagged construct that can
be expressed robustly in human cells and circumvents aforemen-
tioned pitfalls. The FP label enables assay development with a
minimal number of manipulations. The new ﬂuorescent reporter
can be used to rapidly screen candidate drugs or antibodies using
high-throughput platforms, enables visualization of trafﬁcking in
both cells that produce gp120 and cells that bind and endocytose
gp120, and the reporter can be readily adapted to meet the
requirements of new assays.
Results
Gp120-sfGFP construct design and characterization
In vitro production of gp120 at experimentally useful levels was
initially limited by features of the native viral protein. HIV-1
envelope protein expression is signiﬁcantly enhanced by a rev-
responsive element in the mRNA and the small RNA-binding HIV
protein rev (Felber et al., 1989). However, replacement of numer-
ous rare human codons within the gp120 sequence with human
preferred codons increased its expression and eliminated the
requirement for co-expression of rev in mammalian cells (Haas
et al., 1996).
Proper secretion and ﬂuorescent tagging of a viral protein also
present potential challenges. To visualize gp120 in CD4 binding
assays, investigators assumed that tagging gp120 with a FP might
sterically hinder interactions with CD4 (Bowley et al., 2007). It was
also previously suggested that FP-tagged gp120 is not secreted
because the signal sequence (SS) remains attached to the protein
as a transmembrane domain (Wang and Pang, 2008). We sought to
carefully evaluate a FP-tagged gp120 with the goal of improving
the construct in several important ways: 1) addition of human
sugars; 2) discrete and reproducible ﬂuorescent labeling; and
3) development of a platform for easy manipulation of gp120 to
create a powerful adaptable tool for investigators.
We began with a human codon optimized sequence of gp120
JRFL HIV-1 variant (Trkola et al., 1996) containing the native SS
fused upstream of a FP (Fig. 1A). We chose superfolder GFP (sfGFP)
(Pedelacq et al., 2006) because other GFPs frequently misfold and
form dark proteins in the oxidizing environment of the endoplas-
mic reticulum (ER) lumen (Jain et al., 2001), whereas sfGFP is
resistant to formation of nonnative disulﬁde bonds (Aronson et al.,
2011). In addition, gp120-sfGFP has the advantage of a single,
genetically encoded and highly stable FP tag. SfGFP has a much
greater resistance to photobleaching and lower pKa value (5.5)
compared to that of FITC dyes (6.5), which translates to brighter
sfGFP ﬂuorescence in slightly acidic cellular compartments.
For protein production, the human U-2 OS cell line was selected
for high transfection efﬁciency and ability to produce robust yields
of secreted gp120-sfGFP. The gp120-sfGFP plasmid and a control
plasmid expressing the prolactin SS followed by sfGFP (SS-sfGFP)
were transiently transfected in cells (Fig. 1A). Both gp120-sfGFP
and SS-sfGFP were efﬁciently localized to the secretory pathway
and subsequently secreted from cells. Transient transfection of
cells resulted in bright expression of gp120-sfGFP localized to the
ER and the secretory pathway, but not to the plasma membrane
(Fig. 1B). We did not observe a transmembrane form of FP-tagged
gp120 trapped on the cell surface.
N-linked glycosylation of gp120 is required for proper gp120
folding and for binding to CD4 (Li et al., 1993). We conﬁrmed that
gp120-sfGFP is extensively glycosylated by analyzing culture
media and cell lysates by immunoblot (Fig. 1C and D). Gp120-
sfGFP acquired N-linked glycans, and migrated to the expected
molecular weight (144 kDa). Treatment of cells expressing gp120-
sfGFP with tunicamycin, a GlcNAc phosphotransferase inhibitor,
blocks N-glycosylation and produced a shift to a lower molecular
weight band (–CHO) corresponding to species lacking N-linked
glycans (Fig. 1D, Lanes 1 and 2). Finally, prevention of glycosylation
with tunicamycin or removal of sugars with PNGaseF established
that sugars contribute 60 kDa to gp120-sfGFP (Fig. 1E).
The large number of disulﬁde bonds in gp120 presents numer-
ous opportunities for protein misfolding. It has been previously
reported that secreted gp120 contains an aberrant covalent
dimeric form (Finzi et al., 2010). We also observe this species
(Supplementary Fig. 1A). Whereas Finzi et al. observed 20–30%
dimeric form, the sfGFP fusion resulted in up to 70% covalent
dimer. Importantly though, we found that the monomeric form
could be readily puriﬁed using a size fractionation column
(Supplementary Fig. 1B).
To determine the approximate concentration of secreted gp120-
sfGFP collected, serial dilutions of sfGFP samples of known con-
centration (Fig. 1E, Lanes 3–7) were compared with that of PNGase
treated gp120-sfGFP by immunoblot (Fig. 1E, Lane 2) and estab-
lished that concentrated cell media contained 3.4 μg/mL of
secreted gp120-sfGFP. Taken together, we successfully generated a
ﬂuorescent gp120 protein decorated with human N-linked sugars.
Folding and trafﬁcking of gp120-sfGFP in living cells
Until now, trafﬁcking studies of gp120 have been restricted to
ﬁxed cells followed by antibody labeling or gp120 has been
randomly labeled with ﬂuorescent dyes (Hewson et al., 2001).
We readily visualized trafﬁcking of gp120 in live transiently
transfected HeLa cells (Supplementary Fig. 2A). In contrast to a
previous report (Wang and Pang, 2008), we did not detect a
plasma membrane association in expressing cells, consistent with
cleavage of the gp120 SS in the ER by signal peptidase. Gp120-
sfGFP was detected in two compartments, the tubular network of
the ER and small highly mobile vesicles (Supplementary Fig. 2A).
Future studies can exploit gp120-sfGFP to quantify rates of
trafﬁcking to and from secretory organelles in single cells with
sub-second resolution.
Correct folding of proteins is essential for viral production and
function. Assessment of folding can be determined with a variety
of assays that typically require lysis and mixing of millions of cells
followed by SDS-PAGE. While these techniques are undeniably
powerful, they lack single cell resolution and do not permit
interrogation of the same cell at multiple time points. For studies
of gp120 protein folding events, it would be useful to have
complementary live cell reporters. Gp120-sfGFP, when combined
with photobleaching assays, enables quantitative detection of
changes in protein folding within the ER. Fluorescence recovery
after photobleaching (FRAP) can be used to determine effective
diffusion coefﬁcients (Deff values) of ﬂuorescent molecules in cells
(Supplementary Fig. 2B) (Lippincott-Schwartz et al., 2001). We
performed FRAP on gp120-sfGFP in transiently transfected cells
under homeostatic and ER stress (DTT treatment) conditions
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(Supplementary Fig. 2C). In the absence of stress, gp120 is fully
mobile, but diffuses relatively slowly (D¼0.49 μm2/s), presumably
due to its size when decorated with several 1.4 nm N-linked
sugars. The much smaller reporter ER-mRFP diffuses rapidly at
8.5 μm2/s. During acute protein misfolding stress, ER-mRFP diffu-
sion decreases only slightly (6.6 μm2/s) and this was not statisti-
cally signiﬁcant (p¼0.0852). In contrast, gp120 contains nine
disulﬁde bonds (Louwagie et al., 1995) and their formation is
essential for correct gp120 folding (van Anken et al., 2008).
Exposure to DTT (30 min) led to a rapid and profound 5-fold
decrease in D (D¼0.07 μm2/s), consistent with an increase in size
due to a less compact incompletely folded structure, aggregation,
and/or binding to ER chaperones, such as BiP.
Gp120-sfGFP binds CD4-expressing cells
To determine whether the gp120-sfGFP was functionally capable
of binding CD4, TZM-bl cells (HeLa cells stably expressing CD4 and
CCR5), were exposed to gp120-sfGFP, SS-sfGFP or control media for
1 h. Incubation with gp120-sfGFP resulted in bright ﬂuorescence
labeling of the exterior edge of cells (Fig. 2). The ﬂuorescence
intensity of sfGFP corresponded to a concentration gradient of
gp120-sfGP added to the cells (Fig. 2A). The largest two volumes
of 20 and 40 μl, which corresponds to 0.2 and 0.45 μg/mL
of gp120-sfGFP, were readily detected (Fig. 2A). Similar results were
observed with puriﬁed monomeric gp120-sfGFP (Supplementary
Fig. 1D). Subsequent experiments were conducted utilizing
0.45 μg/mL of gp120-sfGFP for maximal signal to noise. Incubation
with SS-sfGFP and control media did not label cells with ﬂuorescence
(Fig. 2B). In addition, the parental cell line HeLa was exposed to 40 ml
of gp120-sfGFP; no ﬂuorescence labeling was observed (Fig. 2C).
To determine the effect of an inhibitory antibody on gp120-sfGFP
binding, TZM-bl cells were co-incubated with gp120-sfGFP and the
anti-gp120 BNAb VRC01. Fluorescent images acquired using equiva-
lent incubation conditions revealed that VRC01 decreased gp120-
sfGFP binding in a dose dependent manner (Fig. 2D). These results
were further conﬁrmed with experiments conducted with puriﬁed
monomeric gp120-sfGFP (Supplementary Fig. 3). Similarly, to deter-
mine the effect of an antimicrobial compound on gp120-sfGFP
binding, 100 mg/mL of cellulose sulfate (CS), a sulfonated polymer
which competitively blocks binding of gp120 to CD4 (Moulard et al.,
2000; Scordi-Bello et al., 2005), also markedly reduced gp120-sfGFP
binding (Fig. 2E). In contrast, binding was unaffected by the CCR5
antagonist Maraviroc (10 μM) as expected (Fig. 2E).
To evaluate gp120-sfGFP binding to primary cells, PHA-
stimulated human PBMC were incubated with gp120-sfGFP, SS-
sfGFP or control media. As previously demonstrated with TZM-bl
cells, incubation of PBMC with gp120-sfGFP resulted in intense GFP
Fig. 1. Secreted gp120-sfGFP is expressed in human cells and acquires N-linked glycans. (A) Human codon optimized gp120, including the native signal sequence, was fused
upstream to sfGFP to create gp120-sfGFP. The control SS-sfGFP construct contains the bovine prolactin signal sequence (SS) followed by sfGFP. (B) Representative image of
transiently transfected U-2 OS cell expressing gp120-sfGFP, scale bar¼10 μm. Media (M) and cell lysates (C) were collected and examined by immunoblotting with anti-GFP
antibody from U-2 OS transiently transfected with (C) gp120-sfGFP and SS-sfGFP or (D) gp120-sfGFP with or without 5 μg/mL tunicamycin (Tm). Shift to lower molecular
weight indicates non-glycosylated (–CHO) gp120-sfGFP. (E) To determine approximate concentration of gp120-sfGFP collected, serial dilutions of puriﬁed sfGFP samples of
known concentration (lanes 3–7) were compared with PNGase treated gp120-sfGFP (lane 2) by immunoblotting with anti-GFP antibody.
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ﬂuorescence (Fig. 2F). The addition of VRC01 (10 and 50 mg/mL)
decreased gp120-sfGFP binding, even when viewing ﬂuorescence
intensity with longer exposure time (Fig. 2F). Moreover, 100 μg/mL
cellulose sulfate, but not 10 μM Maraviroc, also inhibited gp120-
sfGFP binding to PBMC (Fig. 2G). To assess binding speciﬁcity, PBMC
were subdivided into CD8-positive and CD8-negative populations by
positive selection with nanoparticles and PHA-stimulated, before
incubation with gp120-sfGFP and controls. Intense GFP ﬂuorescence
was observed on CD8-negative cells (primarily CD4 T cells) whereas
CD8-positive cells did not exhibit GFP ﬂuorescence (Fig. 2H).
Endocytic trafﬁcking of gp120-sfGFP
In our studies of gp120-sfGFP binding to TZM-bl cells, we
observed that the protein localized to both the cell surface and an
internal perinuclear compartment, most likely endosomes (Fig. 3).
No internal labeling of parent HeLa cells was observed (Fig. 3).
Visualization of binding to and endocytosis of gp120-sfGFP into live
cells may prove useful in studies of HAND pathogenesis and gp120-
mediated loss of CD4 (Hewson et al., 2001). In Fig. 3, gp120-sfGFP
was visualized in various endocytic compartments after an initial
binding step, in which no internalized gp120-sfGFP is
detectable (0 min). Within minutes, gp120-sfGFP localizes to early
endosomes (rab5 and then rab7) and later in lysosomes (identiﬁed
by LAMP-1 association). Gp120 trafﬁcking can be followed out of and
into cells. This reagent or an even brighter variant using a brighter FP,
such as mNeonGreen (Shaner et al., 2013), may enable researchers,
for the ﬁrst time, to follow gp120 production and uptake in a closed
system.
Antibody screening with gp120-sfGFP
To evaluate gp120-sfGFP for high throughput screening of
drugs or antibodies, we performed laser scanning cytometry (LSC),
Fig. 2. gp120-sfGFP binds CD4/CCR5 expressing TZM-bl cells. TZM-bl or HeLa cells were plated in chamber slides and incubated overnight. TZM-bl cells were then exposed
to (A) a range of concentrations of gp120-sfGFP, 5–40 μL (0.2–0.45 μg/mL) and (B) SS-sfGFP and control media. (C) Parental HeLa cells were exposed to 40 mL gp120-sfGFP
and no binding was apparent. TZM-bl cells were co-incubated with 40 μL (0.45 μg/mL) gp120-sfGFP and (D) 10 or 50 mg/mL VRC01 antibody, (E) 100 mg/mL cellulose sulfate
(CS) or 10 mM Maraviroc (MVR). Brightﬁeld and inverted ﬂuorescence images were used to determine the ﬂuorescence binding pattern; images are representative of cells
from at least two independent experiments, scale bar¼10 μm. (E–G) gp120-sfGFP binds primary lymphocytes. After three days of stimulation with PHA, PBMCs were
incubated with 40 μL (0.45 μg/mL) gp120-sfGFP or controls in the presence or absence of the inhibitors (E) VRC01 antibody, (F) cellulose sulfate (CS) or Maraviroc (MVR).
After incubation, PBMCs were transferred to lysine-coated coverglass chamber slides to promote PBMC attachment to the glass for ﬂuorescence microscopy. (G) After 3 days
of PHA-stimulation, CD8-negative (labeled as CD4-positive) and CD8-positive (labeled as CD8-positive) PBMC were incubated with gp120-sfGFP for 1 h. Brightﬁeld paired
with inverted ﬂuorescence images were used to determine the ﬂuorescence binding pattern. Incubation of PBMCs with SS-sfGFP or control media did not result in
ﬂuorescence (data not shown). Images are representative of cells from at least two different donors, scale bar¼10 μm.
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a powerful high throughput ﬂuorescence microscopy technology that
generates large quantitative data sets for adherent cells with sub-
cellular resolution. With several similarities to ﬂow cytometry (Mach
et al., 2010; Pozarowski et al., 2013), the data generated by LCS can be
presented as dot-plots and histograms. TZM-bl cells were plated 18 h
prior to incubationwith gfp120-sfGFP, controls, and inhibitors for 1 h.
As observed with ﬂuorescence microscopy, SS-sfGFP and control
media did not signiﬁcantly label cells (Fig. 4A, top). Incubation of
TZM-bl cells with increasing amounts of gp120-sfGFP resulted in a
corresponding quantitative increase in the number of GFP positive
cells (Fig. 4A, middle and bottom). Gp120-sfGFP labeling of cells
(40 ml) was reduced by co-incubation with established anti-gp120
BNAbs: VRC01, which binds to the CD4 binding site of gp120 (Zhou
et al., 2010), reduced binding of gp120-sfGFP to 26.8% (Fig. 4B). 2G12,
which binds to the outer domain glycans of gp120 at a site distinct
from the CD4 binding site (Sanders et al., 2002; Scanlan et al., 2002),
also decreased the binding to 26.2% (Fig. 4B). Possibly, this reﬂects
distal effects of 2G12 on CD4 binding to gp120, such as by the
introduction of allosteric constraints by the binding of 2G12 to target
gp120 N-glycans, which inhibits residue movements required for the
optimal binding of CD4 to gp120 (Platt et al., 2012). Note that 2G12
cannot bind the sugars that decorate insect cell glycoproteins,
emphasizing the importance of using recombinant gp120 from
human cells. As expected, binding was unaffected by mAb 48d,
which inhibits gp120 binding to the co-receptor CCR5 (Trkola et al.,
1996) (Fig. 4B). Importantly, isotype-matched control antibodies
(claudin-5 and nectin-1) did not affect gp120-sfGFP binding to
TZM-bl cells (Fig. 4B).
Conclusions
In summary, we have described a powerful new ﬂuorescent
tool for studies of gp120 in live cells. The gp120-sfGFP fusion
protein can be readily expressed and visualized in single cells to
enable studies of the endocytic and exocytic trafﬁcking of gp120.
In addition, by combining gp120-sfGFP with photobleaching
techniques in live cells, we found that, unlike another viral
envelope protein, VSV G-GFP, misfolded gp120 is effectively
immobilized in the ER lumen. This difference could arise for at
least two signiﬁcant and not mutually exclusive reasons. First,
diffusion in a membrane is much less sensitive to size changes of a
molecule and this may mask the effects of chaperone binding on
an unfolded protein. However, this seems unlikely to fully account
for the dramatic decrease in misfolded gp120 mobility. Another
explanation is that by uncoupling the protein from the ER
membrane, all the protein can be completely accessed and bound
by ER chaperones. Regions close to the membrane are likely to be
sterically unavailable to chaperones. Thus, the soluble protein
could potentially bind more chaperones, creating a larger and less
mobile complex. More fundamentally, our ﬁndings and those of
others (Finzi et al., 2010; Trkola et al., 1996), suggest that
artiﬁcially untethering viral proteins from membranes, inadver-
tently increases potential folding and misfolding outcomes includ-
ing novel dimers or more extensive protein misfolding. This is not
to suggest that soluble membrane proteins lack utility. Rather, as
with any reagent, characterization of reporters can help avoid
pitfalls and aid interpretation of results.
Curiously, gp120-sfGFP behaved quite differently from another
viral envelope protein, vesicular stomatitis virus G protein (VSV G).
DTT and other inhibitors of post-translational folding modiﬁcations
in the ER disrupt VSV G folding and can induce formation of very
large complexes, which can be detected by ultracentrifuge gradient
separation (de Silva et al., 1993). In a live cell photobleaching study by
Nehls et al., VSV G-GFP mobility did not decrease in cells treated with
DTT and remained highly mobile (Nehls et al., 2000). Our data with
the inert ER-mRFP reporter established that gp120-sfGFP misfolding
did not grossly alter the luminal environment. One explanation is
that integration of VSV G into the ER membrane could dampen the
effects of size changes on diffusion (i.e. a 10-fold increase in size
decreases diffusion by half) (Saffman and Delbruck, 1975). In contrast,
the mobility of soluble proteins is inversely proportional to changes
in molecular size (a 2-fold increase in size decreases mobility by half)
(Einstein, 1905). It is also possible that the extensively glycosylated
gp120 would be effectively much larger in an unfolded state. To date,
the organization and dynamics of few misfolded secretory proteins
Fig. 3. gp120-sfGFP uptake and trafﬁcking in living cells. Endocytosis and colocalization of gp120-sfGFP in TZM-bl cells transiently transfected with Rab5-mRFP, Rab7-mRFP
or LAMP-1-mRFP. Confocal images of cells at different times during incubation reveals progressive trafﬁcking of gp120-sfGFP from early endosomes to lysosomes. Scale
bars¼10 μm.
L.M. Costantini et al. / Virology 476 (2015) 240–248244
have been studied in live cells. Gp120-sfGFP represents a useful new
reagent for basic research and mutants/variants of gp120-sfGFP can
now be assayed for aspects of folding and quality control in their
native environment.
The ﬂuorescent gp120 binding assays described here provide a
robust and rapid quantitative readout of gp120-CD4 binding. We have
outlined the minimal steps to purify and assay gp120-sfGFP and
provided examples of qualitative and quantitative methods to evaluate
gp120-CD4 binding events. More sensitive analysis of binding inhibi-
tors can be performed using live cell ﬂuorescence microscopy with a
high numerical aperture objective. For high-throughput approaches
and large scale screens, LSC and similar technologies can assess effects
with greater speed than possible with manual imaging.
An important feature of the gp120-sfGFP reagent is its adaptability
for new assays. For example, even sfGFP is not ideal for acidic
(pH 4–5.5) endocytic cellular compartments. Thus, one can easily
replace sfGFP with a low pKa FP, i.e. mCherry (pKao4). For testing
other Env variants, the JRFL sequence can be mutated as needed
(Wu et al., 2010). More disparate Env sequences can be synthesized
with human codon optimization. If desired, the gp120-sfGFP could
be modiﬁed for puriﬁcation, i.e. a Hisx6 tag or a Fc tag (Binley et al.,
2006) following the sfGFP protein. Alternatively, the gp120-sfGFP
construct could be afﬁnity-puriﬁed by binding to an anti-gp120
or anti-GFP antibody. Given that there are at least two forms
of gp120-sfGFP (monomers and covalent dimers), puriﬁcation on a
molecular sizing column is likely to be useful for some applications.
We have demonstrated that the material can be readily fractionated
and it is likely that a larger sizing column will increase yield of the
monomer. Equally important, we note that the ratio of dimer
to monomer with our fusion appears higher than that reported
for gp120 alone (Finzi et al., 2010). This raises the possibility that
sfGFP may contribute to dimer formation and we hypothesize the
cysteines in sfGFP may be the cause. In future studies, we seek to
identify monomeric bright cysteine-less ﬂuorescent proteins for
fusions to potentially further improve yield. In conclusion, the
gp120-sfGFP provides a powerful and improved ﬂuorescent tool with
consistent labeling and human sugar modiﬁcations to examine CD4-
binding, cellular uptake, and trafﬁcking within live cells.
Materials and methods
Plasmids
The codon optimized gp120-sfGFP was generated by PCR
ampliﬁcation of JRFL gp120 (Trkola et al., 1996) with forward-
GATCGCTAGCGCCACATGGATGCAATGAAGAGAGGG and reverse-
GATCACCGGTCCCTTCTCCCTCTGCAC primers, the fragment was
Fig. 4. gp120-sfGFP can be used to screen gp120 inhibitors by LSC. TZM-bl cells grown overnight in optical imaging microplates were exposed to (A) a range of
concentrations of gp120-sfGFP in the presence or absence of (B) 10 μg/mL anti-HIV antibodies (VRC01, 2G12, and 48d) or 10 μg/mL isotype-matched control antibodies
(claudin-5 and nectin-1). After 1 h of incubation, media was replaced and nuclei were stained using Hoechst; LSC was then used to identify nuclei and GFP intensities in 10
ﬁelds per well with triplicate wells. The SS-sfGFP control was used to set the negative gate to enable detection of speciﬁc GFP cell labeling. Results are representative of two
independent experiments.
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inserted into sfGFP N1 Clontech vector via NheI/AgeI restriction
sites. The codon-optimized gp120-sfGFP was further modiﬁed to
include the native Hxb2 gp120 signal sequence. PCR ampliﬁcation
of the codon optimized gp120-sfGFP fusion (described above) with
forward-GATCGGTACCTGTGTGGAAG and reverse-GGTTCAGGGGG
AGGTGT was inserted downstream of Hxb2 gp120 signal sequence
with KpnI/NotI restriction sites. The parental vector HXB2 gp120
signal sequence-containing vector was obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH: HXB2-env from Dr. Kathleen Page and Dr. Dan Littman (Page
et al., 1990). SS-sfGFP was previously described (Aronson et al.,
2011). Rab5-mRFP and Rab7-mRFP were produced by the labora-
tory of Dr. Ari Helenius (Vonderheit and Helenius, 2005) and
obtained from Addgene (Cambridge, MA). LAMP-1-mRFP1 was
created by the laboratory of Dr. Walter Mothes (Sherer et al.,
2003). ER-mRFP was previously described (Snapp et al., 2006).
Cells
Peripheral blood mononuclear cells (PBMC) were isolated from
human leukopacks (New York Blood Center) by gradient centrifu-
gation using FicollPaque Plus (Sigma-Aldrich, St. Louis, MO). For
isolation of T cell subpopulations, EasySep Human CD8 Positive
Selection Kit (STEMCELL Technologies, Vancouver, BC) was used as
recommended. Total PBMC or CD8-negaitve and CD8-positive
populations were cultured for 3 days (1106 cells/mL) in phenol
red free RPMI 1640 (Gibco, Life Technologies, Grand Island, NY)
containing 2 mM glutamine, 10% fetal bovine serum (FBS)
(HyClone, Life Technologies), 100 U of penicillin/mL, 100 U of
streptomycin/mL (Life Technologies), and 5 μg/mL phytohae-
magglutinin (PHA) (Sigma-Aldrich) prior to use. TZM-bl (HeLa
cells stably expressing CD4 and CCR5 as well as luciferase and
β-galactosidase under the HIV-1 promoter) cells were obtained
from the NIH AIDS Research and Reference Reagent Program and
cultured as recommended with the exception of using phenol red
free DMEM (Kappes and Wu, 2005). Human bone epithelial cells
(U-2 OS; ATCC) and HeLa cells (ATCC) were cultured in RPMI
medium supplemented with 5 mM glutamine, penicillin/strepto-
mycin, and 10% heat inactivated FBS.
gp120-sfGFP expression and concentration
U-2 OS cells were cultured in RPMI phenol red free media
containing 2% FBS, supplemented with 5 mM glutamine and
penicillin/streptomycin. Gp120-sfGFP or SS-sfGFP plasmids were
transiently transfected with Lipofectamine 2000 (Life Technolo-
gies) according to manufacturer instructions. Two days post-
transfection, culture media was collected and centrifuged at
3000g to remove cellular debris. Media was then concentrated
using centrifugal 15 mL 10 kDa ﬁlter units (Millipore, Billerica,
MA). Media was concentrated 20 , for gp120-sfGFP 40 mL of
media was concentrated to 2 mL and SS-sfGFP and untransfected
media, 10 mL of media was concentrated to 500 μL. Samples were
stored at 4 1C.
Immunoblot
U-2 OS were transfected with gp120-sfGFP in the presence (6 h)
or absence of tunicamycin-treatment (Tm; Calbiochem, La Jolla, CA)
and were lysed in 1% SDS, 0.1 M Tris, pH 8.0 with 100 mM DTT.
Proteins were separated using a 6% Tris-tricine gel, transferred to
nitrocellulose, probed with an anti-GFP antibody (a generous gift
from Ramanujan S. Hegde, Laboratory of Molecular Biology,
Cambridge, UK) and horseradish peroxidase-labeled anti-rabbit
secondary antibody (Jackson Immunoresearch Laboratories, West
Grove, PA), and developed using enhanced chemiluminescent
reagents (Pierce, Rockford, IL), and exposed to X-ray ﬁlm. The
relative concentration of gp120-sfGFP was approximated by com-
parison with puriﬁed sfGFP of a known concentration. For gp120-
sfGFP, the concentrated media was determined to contain 3.4 μg/
mL. Experiments were conducted with a dynamic range of dilutions
corresponding to 0.2–0.45 μg/mL.
Live cell ﬂuorescence microscopy
PBMCs were plated and exposed to gp120-sfGFP in round-
bottom 96-well tissue culture plates for 1 h at 37 1C before being
moved to 0.1% poly-L-lysine coated 8-well Nunc LabTek #1.0
borosilicate coverglass chambers (Nunc, Life Technologies, Roche-
ster, NY). TZM-bl cells were grown overnight in 8-well Nunc
LabTek #1.0 borosilicate coverglass chambers, cells were exposed
to gp120-sfGFP or controls in the presence or absence of the
indicated inhibitor for 1 h at 37 1C and ﬁnally, phenol red free
media was replaced for microscopy. Gp120-sfGFP images were
acquired using an Axiovert 200 wideﬁeld ﬂuorescence microscope
(Carl Zeiss Microimaging, Inc., Thornwood, NY) with a 63 oil
immersion 1.4 NA objective, and 470/40 excitation, 525/50 emis-
sion bandpass ﬁlter for sfGFP. Transiently transfected HeLa cells
expressing gp120-sfGFP were imaged in a 37 1C environmentally
controlled chamber of a confocal microscope system (Zeiss LSM
5 LIVE microscope with Duoscan attachment; Carl Zeiss Micro-
Imaging, Inc.) with a 63X/1.4 NA oil objective and a 489 nm
100 mW diode laser with a 495–555 and 520–555 nm bandpass
ﬁlter. Image analysis and composite ﬁgures were prepared using
ImageJ (National Institutes of Health), Photoshop CS4 and Illus-
trator CS4 software (Adobe Systems, San Jose, CA).
FRAP was performed on the Zeiss LIVE with Duoscan. Data
were analyzed using an in homogenous diffusion simulation
(Siggia et al., 2000).
Antibodies and drugs
HIV-1 gp120 monoclonal antibody 2G12, 48D, and VRC01 were
obtained from the NIH AIDS Reagent and Reference Program. Anti-
claudin-5 and anti-nectin-1 antibodies (Santa Cruz Biotechnology,
Dallas, TX) were used as isotype-matched control antibodies.
Cellulose sulfate (Acros Organics, Life Technologies, Rockford, IL)
was rehydrated in 1X PBS. Maraviroc was provided by ViiV
Healthcare.
Laser scanning cytometry
TZM-bl cells were plated in glass-bottom 96-well optical
imagining microplates (Brooks Life Science, Chelmsford, MA) and
incubated at 37 1C O/N. Cells were exposed to constructs or control
media in the presence or absence of the indicated inhibitors or
controls for 1 h at 37 1C. Cells were stained with 0.1 μg/mL
Hoechst for 30 min, washed, and phenol red free media supple-
mented with 10 mM HEPES was added. Cells were then imaged
with the iCys Research Imaging Cytometer (CompuCyte, Thorlabs
Inc., Newton, NJ) using a 60X (Fig. 4) or 40X (Supplementary Fig. 1)
0.9 NA objective. sfGFP was excited using a laser at 488 nm and
ﬂuorescence was collected with a 515–545 nm emission ﬁlter. Ten
ﬁelds were imaged with biological triplicates for each condition
speciﬁed. Using the iCyte (CompuCyte) imaging software indivi-
dual cells were identiﬁed and analyzed for green ﬂuorescence.
Data were exported to FloJo (Treestar, Ashland, OR) for analysis of
cytometric data.
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